Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

January 25th 2023

Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

January 25th 2023

Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.

Dr. Flinn on the FDA Approval of Zanubrutinib in CLL/SLL

January 25th 2023

Ian Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

January 19th 2023

The FDA has approved zanubrutinib for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

The Medicines and Healthcare Products Regulatory Agency has approved zanubrutinib in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia and the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20–based therapy.

Ibrutinib Plus Venetoclax Provides Additional Fixed-Duration Regimen for Elderly Patients With CLL

January 18th 2023

Carsten Niemann, MD, PhD, discusses the significance of new data from the GLOW trial, the potential relationship between treatment regimen, minimal residual disease status, and survival outcomes, and the importance of research into precision medicine approaches in chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

January 18th 2023

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.

Brief Overview of Chronic Lymphocytic Leukemia

January 18th 2023

Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.

Dr. Jacobs on the Continued Impact of the CAPTIVATE trial in CLL

January 16th 2023

Ryan Jacobs, MD, discusses the implications of next-line treatment strategies following long-term data of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.

BGB-11417 Shows Encouraging Early Efficacy and Tolerability in CLL

January 9th 2023

Chan Y. Cheah, MD, MBBS, discusses the the phase 1 BGB-11417-101 trial, which showed that the BCL-2 inhibitor BGB-11417, administered alone or in combination with the BTK inhibitor zanubrutinib, induced promising response rates and was well tolerated patients with chronic lymphocytic leukemia.

Dr. Niemann on Notable Findings from the GLOW Trial in CLL

January 6th 2023

Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.

Japan Approves Acalabrutinib for Treatment-Naïve CLL

January 6th 2023

Japan’s Ministry of Health, Labor, and Welfare has approved acalabrutinib for the treatment of previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

January 6th 2023

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study

January 5th 2023

Nicole Lamanna, MD, reviews the results of the phase 3 study evaluating the use of zanubrutinib versus ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

December 31st 2022

Driven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.

Lisaftoclax With or Without Rituximab or Acalabrutinib Elicits Favorable Responses and Safety in CLL/SLL

December 23rd 2022

Lisaftoclax alone or in combination with acalabrutinib or rituximab was active across a range of doses and displayed a tolerable safety profile in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Burke on the Underrepresentation of Elderly Patients in Clinical Trials for Lymphoma

December 19th 2022

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Dr. Niemann on Ibrutinib Plus Venetoclax Vs Chlorambucil and Obinutuzumab in Mutated CLL

December 19th 2022

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.

Emerging Agents Signal Promising Opportunities to Expand Treatment Options for CLL

December 15th 2022

Anthony Mato, MD, MSCE, discusses the relapsed refractory setting compared with the frontline setting and promising agents such as pirtobrutinib and zanubrutinib.